ENTX Aug 2024 2.500 call
| Previous Close | 0.8000 |
| Open | 0.7500 |
| Bid | 0.1500 |
| Ask | 0.9000 |
| Strike | 2.50 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.7500 - 0.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.1k |
ZacksVanda (VNDA) Rises on Positive Data From Motion Sickness Study
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
ZacksAre Medical Stocks Lagging Entera Bio (ENTX) This Year?
Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
GlobeNewswireEntera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women’s health research and drug development experience to Entera. She has successfully advanced the d
